

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptanscl625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced

NEWS 33 JAN 28 USGENE now provides USPTO sequence data within 3 days
of publication
NEWS 34 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 35 JAN 28 MEDLINE and LMedLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:44:20 ON 31 JAN 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:44:29 ON 31 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2008 HIGHEST RN 1001156-45-1
DICTIONARY FILE UPDATES: 30 JAN 2008 HIGHEST RN 1001156-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10558846A.str



```

chain nodes :
13 14 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
9-13 13-14 14-15 14-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
4-5 4-7 5-6 5-9 7-8 8-9 9-13 13-14 14-15 14-16
normalized bonds :
1-2 1-6 2-3 3-4

```

G1:O,CH2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 13:CLASS
14:CLASS 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,CH2

Structure attributes must be viewed using STN Express query preparation.

=> s sss sam l1

SAMPLE SEARCH INITIATED 18:44:52 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8985 TO ITERATE

22.3% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 174019 TO 185381

PROJECTED ANSWERS: 11497 TO 14559


L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indene-1-acetic acid, 5-(3,5-difluorophenyl)-2,3-dihydro-6-(6-quinolinyl)-, ethyl ester

MF C28 H23 F2 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.92

1.13

FILE 'STNGUIDE' ENTERED AT 18:45:37 ON 31 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jan 25, 2008 (20080125/UP).

=> logoff y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST	ENTRY	SESSION
	0.78	1.91

STN INTERNATIONAL LOGOFF AT 18:53:28 ON 31 JAN 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptanscl625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Caplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Caplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Caplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Caplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Caplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available

NEWS 30 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
 NEWS 31 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
 NEWS 32 JAN 28 MARPAT searching enhanced
 NEWS 33 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
 NEWS 34 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 35 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:32:37 ON 01 FEB 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:32:52 ON 01 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6

DICTIONARY FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10558846B.str



chain nodes :

10 11 12 13 15 16 17 18 19 20 21

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

3-20 8-16 8-17 9-10 9-15 10-11 10-18 10-19 11-12 11-13 20-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

3-20 5-7 6-9 7-8 8-9 8-16 8-17 9-10 9-15 10-11 10-18 10-19 11-12 11-13 20-21

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,CH2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
 20:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O, CH2

Structure attributes must be viewed using STN Express query preparation.

=> s sss sam l1

SAMPLE SEARCH INITIATED 17:33:15 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5130 TO ITERATE

39.0% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 98305 TO 106895


PROJECTED ANSWERS: 2109 TO 3533

L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)-
MF C29 H35 N3 O3

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10558846C.str



chain nodes :

10 11 12 13 15 16 17 18 19 20 21 22

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

3-20 8-16 8-17 9-10 9-15 10-11 10-18 10-19 11-12 11-13 20-21 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

3-20 5-7 6-9 7-8 8-9 8-16 8-17 9-10 9-15 10-11 10-18 10-19 11-12 11-13
20-21 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,CH2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:Atom

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR



G1 O, CH2

Structure attributes must be viewed using STN Express query preparation.

=> s sss sam l3

SAMPLE SEARCH INITIATED 17:39:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4867 TO ITERATE

41.1% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 93157 TO 101523

PROJECTED ANSWERS: 1772 TO 3094

L4 50 SEA SSS SAM L3


=> d scan

L4 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]-, (1S)-

MF C24 H22 F3 N O3 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L4 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl-1,5-dimethyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)-
 MF C32 H34 N2 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indene-1-acetic acid, 2,3-dihydro-6-(1H-indazol-5-yl)-5-[[4-(trifluoromethyl)phenyl]methoxy]-, (1S)-
 MF C26 H21 F3 N2 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indene-1-acetic acid, 5-(cyclopentyloxy)-6-(1-ethyl-1H-indol-5-yl)-2,3-dihydro-, (1S)-
 MF C26 H29 N O3

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=>

Uploading C:\Program Files\Stnexp\Queries\10558846D.str



chain nodes :

10 11 12 13 15 16 17 18 19 20 21 22 25 26 27

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

1-25 2-26 3-20 4-27 8-16 8-17 9-10 9-15 10-11 10-18 10-19 11-12 11-13
20-21 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

1-25 2-26 3-20 4-27 5-7 6-9 7-8 8-9 8-16 8-17 9-10 9-15 10-11 10-18
10-19 11-12 11-13 20-21 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,CH2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:Atom 25:CLASS 26:CLASS 27:CLASS

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



G1 O,CH2

Structure attributes must be viewed using STN Express query preparation.

=> s sss sam 15

SAMPLE SEARCH INITIATED 17:41:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4867 TO ITERATE

41.1% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


19 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 93157 TO 101523
PROJECTED ANSWERS: 517 TO 1331

L6 19 SEA SSS SAM L5

=> d scan

L6 19 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Benzofuranacetic acid, 2,3-dihydro-6-[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methoxy]-, methyl ester
MF C24 H21 F3 O5





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10558846E.str



chain nodes :

10 11 12 13 15 16 17 18 19 20 23 24 25

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

1-23 2-24 3-18 4-25 9-10 9-15 10-11 10-16 10-17 11-12 11-13 18-19 19-20

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

1-23 2-24 3-18 4-25 5-6 5-7 6-9 7-8 8-9 9-10 9-15 10-11 10-16 10-17
11-12 11-13 18-19 19-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5

G1:O,CH2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:Atom 23:CLASS 24:CLASS 25:CLASS

L7 STRUCTURE UPLOADED


=> s sss sam l7
 SAMPLE SEARCH INITIATED 17:45:09 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 4965 TO ITERATE

40.3% PROCESSED 2000 ITERATIONS 18 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 95075 TO 103525
 PROJECTED ANSWERS: 492 TO 1294

L8 18 SEA SSS SAM L7

=> d l7
 L7 HAS NO ANSWERS
 L7 STR



G1 O, CH2

Structure attributes must be viewed using STN Express query preparation.


=> d scan l18
 L18 NOT FOUND

The L-number has not been used in the current session or has been deleted.

=> d scan l8

L8 18 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(4-propylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)-
 MF C27 H32 N2 O3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L8 18 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-thiazolyl]ethoxy]-, ethyl ester, (1S)-
 MF C26 H29 N O3 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 18 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(methylamino)phenyl]-4-oxazolyl]ethoxy]-, (1S)-
 MF C24 H26 N2 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L8 18 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-Benzofuranacetic acid, 2,3-dihydro-6-[[4-[4-(trifluoromethyl)phenyl]-2-

thiazolyl]methoxy]-
MF C21 H16 F3 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 18 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-
MF C24 H24 F N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s sss full 17

FULL SEARCH INITIATED 17:46:41 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 98783 TO ITERATE

100.0% PROCESSED 98783 ITERATIONS

655 ANSWERS

SEARCH TIME: 00.00.03

L9 655 SEA SSS FUL L7

=> fil save 19 yasul0558846/a

'SAVE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):end

=> save 19 yasul0558846/a

ANSWER SET L9 HAS BEEN SAVED AS 'YASU10558846/A'

```
=> fil caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          190.78      190.99
```

FILE 'CAPLUS' ENTERED AT 17:49:33 ON 01 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Feb 2008 VOL 148 ISS 6
 FILE LAST UPDATED: 31 Jan 2008 (20080131/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s 19
L10      15 L9
```

```
=> s 19 and (ay<2003 py<2003 or pry<2003)
NUMERIC VALUE NOT VALID 'AY'
Numeric values may contain 1-8 significant figures. If range notation is used, both the beginning and the end of the range must be specified, e.g., '250-300/MW'. Expressions such as '250-/MW' are not allowed. To search for values above or below a given number, use the >, =>, <, or <= operators, e.g., 'MW => 250'. Text terms cannot be used in numeric expressions. If you specify a unit, it must be dimensionally correct for that field code. To see the unit designations for field codes in the current file, enter "DISPLAY UNIT ALL" at an arrow prompt (=>).
```

```
=> s 19 and (ay<2003 or pr<2003 or pry<2003)
'2003' NOT A VALID FIELD CODE
      15 L9
      4475620 AY<2003
      0 PR<2003
      3950746 PRY<2003
L11      6 L9 AND (AY<2003 OR PR<2003 OR PRY<2003)
```

```
=> d ibib abs hitstr 1-6
```

```
L11 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:      2004:878169 CAPLUS Full-text
DOCUMENT NUMBER:      141:366218
TITLE:                 Preparation of substituted (hetero)aromatic compounds
                        that modulate PPAR activity
INVENTOR(S):           Bratton, Larry D.; Cheng, Xue-Min; Erasga, Noe;
```


PATENT ASSIGNEE(S): Filzen, Gary F.; Geyer, Andrew G.; Lee, Chitase;
 SOURCE: Trivedi, Bharat K.; Unangst, Paul C.
 Warner Lambert Company LLC, USA
 U.S. Pat. Appl. Publ., 90 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209936	A1	20041021	US 2004-774260	20040206
US 7244763	B2	20070717		
US 2003225158	A1	20031204	US 2003-347749	20030122 <--
US 6875780	B2	20050405		
CA 2522118	A1	20041028	CA 2004-2522118	20040405
WO 2004091604	A1	20041028	WO 2004-IB1178	20040405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1620086	A1	20060201	EP 2004-725756	20040405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009486	A	20060502	BR 2004-9486	20040405
JP 2006524220	T	20061026	JP 2006-506486	20040405
NL 1025961	A1	20041026	NL 2004-1025961	20040416
NL 1025961	C2	20050215		

PRIORITY APPLN. INFO.:

US 2003-463641P	P	20030417
US 2002-370508P	P	20020405 <--
US 2002-386026P	P	20020605 <--
WO 2004-IB1178	W	20040405

OTHER SOURCE(S): CASREACT 141:366218; MARPAT 141:366218
 GI



AB Title compds. I [X0-2 = absent, O, S, amino, etc.; Ar1-2 = (hetero)aryl, etc.; V1 = absent, (un)saturated hydrocarbon chain, etc.; T = (un)saturated, (un)substituted hydrocarbon, etc.; R1-3 = H, alkyl, alkoxy, etc.; R7-8 = H, alkyl, halo, etc.; n = 0-5; q = 0-10; p = 0-10] are prepared For instance, [7-[(4-(4-Chlorophenyl)-4-oxobutyl)sulfanyl]indan-4-yloxy]acetic acid is prepared in 5 steps from 4-hydroxyindan-1-one, Me bromoacetate and 4-chloro-1-(4-chlorophenyl)butan-1-one. Compds. of the invention exhibit IC50 < 9,344 nM for PPAR β and IC50 of < 15,000 nM for PPAR α . I are useful for the treatment of dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia.


IT 779187-48-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted (hetero)aromatic compds. that modulate ppar activity for the treatment of, e.g., dyslipidemia)

RN 779187-48-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methoxy]- (CA INDEX NAME)




IT 779202-60-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted (hetero)aromatic compds. that modulate ppar activity for the treatment of, e.g., dyslipidemia)

RN 779202-60-7 CAPLUS



CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methoxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:565052 CAPLUS Full-text
 DOCUMENT NUMBER: 141:123483
 TITLE: Preparation of indaneacetic acid derivatives and their use as pharmaceutical agents
 INVENTOR(S): Cantin, Louis-David; Choi, Soongyu; Clark, Roger B.; Hentemann, Martin F.; Ma, Xin; Rudolph, Joachim; Liang, Sidney X.; Akuche, Christiana; Lavoie, Rico C.; Chen, Libing; Majumdar, Dyuti; Wickens, Philip L.
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 230 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058174	A2	20040715	WO 2003-US40842	20031219 <--
WO 2004058174	A3	20041202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2510793	A1	20040715	CA 2003-2510793	20031219 <--
AU 2003299790	A1	20040722	AU 2003-299790	20031219 <--
EP 1578715	A2	20050928	EP 2003-800063	20031219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516251	T	20060629	JP 2004-563903	20031219 <--
US 2006084680	A1	20060420	US 2005-537630	20050603 <--
PRIORITY APPLN. INFO.:			US 2002-435310P	P 20021220 <--
			WO 2003-US40842	W 20031219
OTHER SOURCE(S): MARPAT 141:123483				
GI				



AB The title compds. [I; R1, R2 = H, alkyl, cycloalkyl; L = (CH2)mX, Y(CH2)nX, etc.; X = O, S, SO, SO2, Y = O, S, SO, SO2, (un)substituted NH; m = 1-3; n = 2-4; Ar = (un)substituted Ph, 5-6 membered heteroaryl containing up to there N atoms] which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases, were prepared and formulated. Thus, coupling Et {(1S)-5-[3-(4-bromo-2-methoxyphenoxy)propoxy]-2,3-dihydro-1H-inden-1-yl}acetate (preparation given) with 3-thiopheneboronic acid in the presence of PdCl2(dppf).CH2Cl2, NaHCO3 in DME/H2O followed by treatment of the resulting ester with LiOH afforded (1S)-II.

IT 724470-54-6P 724470-64-8P 724470-70-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 724470-54-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[1-(2-chloro-5-methyl-4-pyrimidinyl)-4-piperidinyl]oxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-64-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(6-chloro-2-pyridinyl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-70-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-methoxyphenyl)-3-methyl-2-pyridinyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 724470-55-7P 724470-56-8P 724470-57-9P
 724470-58-0P 724470-59-1P 724470-60-4P
 724470-61-5P 724470-65-9P 724470-66-0P
 724470-71-7P 724470-72-8P 724470-73-9P
 724470-74-0P 724470-75-1P 724470-76-2P
 724470-77-3P 724470-78-4P 724470-79-5P
 724470-80-8P 724470-81-9P 724470-82-0P
 724470-83-1P 724470-84-2P 724470-85-3P
 724470-93-3P 724470-94-4P 724470-96-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 724470-55-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[1-[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]-4-piperidinyl]oxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 724470-56-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[1-(2S)-1-[2-(4-ethylphenyl)-5-methyl-4-

pyrimidinyl]-2-pyrrolidinyl]methoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-57-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[[1-[2-(4-fluorophenyl)-5-methyl-4-pyrimidinyl]-4-piperidinyl]oxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-58-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[[1-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]oxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-59-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[[1-[2-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]-4-piperidinyl]oxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-60-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[1-[2-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]-4-piperidinyl]oxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-61-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[1-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]-4-piperidinyl]oxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-65-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(4-ethylphenyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-66-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(methylphenylamino)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-71-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-methoxyphenyl)-3-methyl-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-72-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(3-methyl-2-pyridinyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-73-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-methylphenyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-74-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(4-acetylphenyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-75-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-methoxyphenyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-76-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(1,3-benzodioxol-5-yl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-77-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(4-chlorophenyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-78-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(4-fluorophenyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-79-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(6-phenyl-2-pyridinyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-80-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(3-furanyl)-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-81-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-82-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(3-thienyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-83-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-morpholinyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-84-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(1-piperidinyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-85-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[6-(4-methyl-1-piperazinyl)-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-93-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[6-(4-ethylphenyl)-3-methyl-2-pyridinyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-94-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[3-methyl-6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 724470-96-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(6-ethyl-2-pyridinyl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:101148 CAPLUS Full-text



DOCUMENT NUMBER: 140:163867

TITLE: Preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivatives as antidiabetic agents

INVENTOR(S): Wickens, Philip; Cantin, Louis-David; Chuang, Chih-Yuan; Dai, Miao; Hentemann, Martin F.; Kumarasinghe, Ellalahewage; Liang, Sidney X.; Lowe, Derek B.; Shelekhin, Tatiana E.; Wang, Yamin; Zhang, Chengzhi; Zhang, Hai-Jun; Zhao, Qian

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 204 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011446	A1	20040205	WO 2003-US23342	20030725 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003263814	A1	20040216	AU 2003-263814	20030725 <--
PRIORITY APPLN. INFO.:			US 2002-399095P	P 20020726 <--
			WO 2003-US23342	W 20030725
OTHER SOURCE(S):		MARPAT 140:163867		
GI				



AB Title compds., e.g., I [X = O, S; n = 1-3; R1 = carboxy, carboxamide, alkylamino, etc.; R2-3 = H, F, alkyl; R4-6 = H, alkyl; R7 = H, alkoxy, OH, etc.; R9 = H, Br, Cl, I, alkyl, etc.; R10 = H, OSO2CF3, etc.; R11 = H, alkyl, etc.; R12 = naphthyl, pyridyl, etc.] are prepared For instance, Et (S)-[5-hydroxy-2,3-dihydro-1H-inden-1-yl]acetate (preparation given) is coupled to 4-chloromethyl-5-methyl-2-phenyloxazole (preparation given; DMF, K2CO3, 3 h, 80°) to give II. I are useful in the treatment of diseases such as diabetes, diabetes-related disorders, obesity, hyperlipidemia and cardiovascular diseases.

IT 652980-38-6P, Ethyl (S)-[5-[(5-methyl-2-phenyl-1,3-oxazol-4-


yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-82-3P,
 Ethyl (S)-[5-[2-(2-iodo-5-methyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-86-7P, Ethyl (S)-[5-[2-[2-(2,4-dimethylphenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-16-6P, Ethyl (S)-[5-[(2-bromo-1-pentyl-1H-imidazol-5-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-23-5P, Ethyl (S)-[5-[2-[2-(4-bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-34-8P, (S)-[5-[2-[2-[4-(Benzylamino)phenyl]-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-39-3P, (S)-[5-[2-[2-(4-Allylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-73-5P 652982-94-0P, Ethyl (S)-[5-[2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-95-1P, Ethyl (S)-[5-[2-[4-(4-tert-butylphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivs. as antidiabetic agents)

RN 652980-38-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-82-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(2-iodo-5-methyl-1H-imidazol-4-yl)ethoxy]-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-86-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2,4-dimethylphenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-16-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[(2-bromo-1-pentyl-1H-imidazol-5-yl)methoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-23-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-34-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-[(phenylmethyl)amino]phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-39-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-(2-propenyl)phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-73-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-94-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-95-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-[4-(1,1-dimethylethyl)phenyl]-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 652980-39-7P, (S)-[5-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-28-7P

652981-33-4P, (S)-[5-[2-(5-Phenethyl-2-phenyloxazol-4-yl)ethoxy]indan-1-yl]acetic acid 652981-34-5P,

(S)-[5-[2-[2-(4-Chlorophenyl)-5-[2-(4-methoxyphenyl)ethyl]oxazol-4-

yl]ethoxy]indan-1-yl]acetic acid 652981-35-6P,
 (S)-[5-[2-[2-(4-Chlorophenyl)-5-[2-(2,6-dichlorophenyl)ethyl]oxazol-4-yl]ethoxy]indan-1-yl]acetic acid 652981-36-7P,
 (S)-[5-[2-[2-(4-Chlorophenyl)-5-(2-m-tolyethyl)oxazol-4-yl]ethoxy]indan-1-yl]acetic acid 652981-37-8P, (S)-[5-[2-[2-(4-Chlorophenyl)-5-(2-p-tolyethyl)oxazol-4-yl]ethoxy]indan-1-yl]acetic acid 652981-38-9P, (S)-[5-[2-[2-(4-Chlorophenyl)-5-[2-(4-chlorophenyl)ethyl]oxazol-4-yl]ethoxy]indan-1-yl]acetic acid 652981-39-0P, (S)-[5-[2-[5-Methyl-2-(6-phenyl-3-pyridinyl)-1,3-oxazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-47-0P, (S)-[5-[2-[2-[(Cyclohexylcarbonyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-49-2P, (S)-[5-[2-(2-Amino-5-methyl-1,3-thiazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid trifluoroacetate 652981-50-5P, Ethyl (S)-[5-[2-[2-[(Anilinocarbonyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-51-6P, (S)-[5-[2-[2-[(Anilinocarbonyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-52-7P, (S)-[5-[2-[5-Methyl-2-[(phenylsulfonyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-53-8P, (S)-[5-[2-[5-Methyl-2-[(methylsulfonyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-54-9P, (S)-[5-[2-[2-[(4-Methoxybenzoyl)amino]-5-methylthiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-55-0P, (S)-[5-[2-[2-(Benzoylamino)-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-56-1P, (S)-[5-[2-[2-[(4-Fluorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-57-2P, (S)-[5-[2-[2-(Acetylamino)-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-58-3P, (S)-[5-[2-[2-[(Cyclobutylcarbonyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-59-4P, (S)-[5-[2-[2-[(1,1'-Biphenyl-4-yl)carbonyl]amino]-5-methylthiazol-4-yl]ethoxy]-2,3-dihydro-1H-indene-1-yl]acetic acid 652981-60-7P, (S)-[5-[2-[2-[(2-Methoxybenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-61-8P, (S)-[5-[2-[2-[(4-Chlorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-62-9P, (S)-[5-[2-[2-[(3,4-Dichlorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-63-0P, (S)-[5-[2-[2-[(3-Methoxybenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-64-1P, (S)-[5-[2-[5-Methyl-2-[(naphthalen-1-yl)carbonyl]amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-65-2P, (S)-[5-[2-[5-Methyl-2-[(3-methylbenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-66-3P, (S)-[5-[2-[5-Methyl-2-[(4-methylbenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-67-4P, (S)-[5-[2-[5-Methyl-2-[(4-nitrobenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-68-5P, (S)-[5-[2-[5-Methyl-2-[(3-nitrobenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-69-6P, (S)-[5-[2-[5-Methyl-2-[(2-nitrobenzoyl)amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-70-9P, (S)-[5-[2-[2-[(3-Chlorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-71-0P, (S)-[5-[2-[2-[(2-Chlorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-72-1P, (S)-[5-[2-[2-[(2-Fluorobenzoyl)amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-73-2P, (S)-[5-[2-[5-Methyl-2-[(2-

methylbenzoyl amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-74-3P, (S)-[5-[2-[5-Methyl-2-[[[(4-methylphenyl)amino]carbonyl]amino]-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-75-4P, (S)-[5-[2-[2-[[[(4-Fluorophenyl)amino]carbonyl]amino]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-84-5P, Ethyl (S)-[5-[2-[2-(4-methoxyphenyl)-4-methyl-1-pentyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-85-6P, Ethyl (S)-[5-[2-(2-iodo-5-methyl-1-pentyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-87-8P, (S)-[5-[2-[2-(2,4-Dimethylphenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-96-9P, [5-[2-[5-Methyl-2-(4-methoxyphenyl)-1-pentyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-97-0P, [5-[2-[2-(4-Methoxyphenyl)-4-methyl-1-pentyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-98-1P, (S)-[5-[2-(1-Benzyl-5-methyl-2-phenyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652981-99-2P, (S)-[5-[2-(1-Benzyl-4-methyl-2-phenyl-1H-imidazol-5-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-00-8P, (S)-[5-[2-[1-Benzyl-5-methyl-2-[4-(methylsulfonyl)phenyl]-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-01-9P, (S)-[5-[2-[1-Benzyl-2-(3-nitrophenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-02-0P, Ethyl (S)-[5-[2-[2-(4-methoxyphenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-03-1P, (S)-[5-[2-[5-Methyl-2-(4-methylphenyl)-1-pentyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-04-2P, (S)-[5-[2-[2-(4-Methoxyphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-05-3P, (S)-[5-[2-[2-(1,1'-Biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-06-4P, (S)-[5-[2-[2-(4-Ethylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-07-5P, Ethyl (S)-[5-[2-[2-(1,1'-biphenyl-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-09-7P, Ethyl (S)-[5-[2-[2-(4-ethylphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-10-0P, (S)-[5-[2-(1,5-Dimethyl-2-phenyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-11-1P, (S)-[5-[2-[2-(4-Ethylphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-12-2P, (S)-[5-[2-[2-(1,1'-Biphenyl-4-yl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-13-3P, (S)-[5-[2-[2-(4-Methoxyphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-17-7P, (S)-[5-[(1-Pentyl-2-phenyl-1H-imidazol-5-yl)methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-18-8P, (S)-[5-[[2-(4-Methoxyphenyl)-1-pentyl-1H-imidazol-5-yl]methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-19-9P, (S)-[5-[[1-Pentyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-20-2P, (S)-[5-[[2-(1,3-Benzodioxol-5-yl)-1-pentyl-1H-imidazol-5-yl]methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-21-3P, (S)-[5-[[2-(3,4-Dimethylphenyl)-1-pentyl-1H-imidazol-5-yl]methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-22-4P, (S)-[5-[[1-Pentyl-2-(4-pyridinyl)-1H-imidazol-5-yl]methoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-31-5P, (S)-[5-[2-[1,4-Dimethyl-2-(4-methylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-33-7P, Ethyl (S)-[5-[2-[2-[4-(benzylamino)phenyl]-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652982-35-9P, (S)-[5-[2-[2-(4-Aminophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic


acid 652982-36-0P, Ethyl (S)-[5-[2-[2-(4-vinylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate
 652982-37-1P, (S)-[5-[2-[2-(4-Vinylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652982-38-2P, Ethyl (S)-[5-[2-[2-(4-allylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate
 652982-40-6P, (S)-[5-[2-[2-(4-Propylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652982-47-3P, (S)-[5-[2-[2-(4-Bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652982-48-4P, (S)-[5-[2-[1,4-Dimethyl-2-[4-(1H-pyrrol-2-yl)phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652982-74-6P, (S)-[5-[2-[3-Phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-80-4P, (S)-[5-[2-(5-Ethoxy-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydroinden-1-yl]acetic acid 652982-81-5P, (S)-4-[1-[2-[[1-(Carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-ethoxy-1H-pyrazol-3-yl]benzoic acid
 652982-82-6P, (S)-[5-[2-(4-Fluoro-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-83-7P, (S)-[5-[2-(4-Chloro-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-84-8P, (S)-[5-[2-(4-Bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-85-9P, (S)-[5-[2-[5-Methoxy-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652982-86-0P, (S)-[5-[2-[5-Methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652982-87-1P, (S)-[5-[2-[4-Fluoro-5-methoxy-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652982-88-2P, (S)-[5-[2-[4-Fluoro-5-methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-89-3P, (S)-[5-[2-[4-Bromo-5-methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652982-90-6P, (S)-[5-[2-(5-Methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652982-96-2P, (S)-[5-[2-[4-(4-tert-Butylphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652982-97-3P, (S)-[5-[2-[4-(4-Methoxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652982-99-5P, (S)-[5-[2-[3,5-Dimethyl-4-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-01-2P, (S)-[5-[2-[4-(1,3-Benzodioxol-5-yl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652983-02-3P, (S)-[5-[2-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-03-4P, (S)-[5-[2-[4-(4-Ethylphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-04-5P, (S)-[5-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-05-6P, (S)-4-[1-[2-[[1-(Carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-3,5-dimethyl-1H-pyrazol-4-yl]benzoic acid
 652983-06-7P, (S)-[5-[2-[3,5-Dimethyl-4-(4-methylphenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652983-07-8P, (S)-[5-[2-[4-(2-Methoxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
 652983-08-9P, (S)-[5-[2-[3,5-Dimethyl-4-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652983-13-6P, [6-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydrobenzofuran-3-yl]acetic acid 654650-48-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indane, dihydrobenzofuran and tetrahydronaphthalene
carboxylic acid derivs. as antidiabetic agents)

RN 652980-39-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-28-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-(2-phenylethyl)-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-33-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-phenyl-5-(2-phenylethyl)-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-34-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-[2-(4-methoxyphenyl)ethyl]-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-35-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-[2-(2,6-dichlorophenyl)ethyl]-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-36-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-[2-(3-methylphenyl)ethyl]-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-37-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-[2-(4-methylphenyl)ethyl]-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-38-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-[2-(4-chlorophenyl)ethyl]-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-39-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(6-phenyl-3-pyridinyl)-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-47-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(cyclohexylcarbonyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 652981-49-2 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-(2-amino-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, (1S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 652981-48-1

CMF C17 H20 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 652981-50-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[[(phenylamino) carbonyl] amino]-4-thiazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-51-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[[(phenylamino) carbonyl] amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-52-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-
[(phenylsulfonyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-53-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-
[(methylsulfonyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-54-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[(4-methoxybenzoyl)amino]-5-
methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-55-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(benzoylamino)-5-methyl-4-
thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-56-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(4-fluorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-57-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(acetylamino)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-58-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(cyclobutylcarbonyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-59-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-60-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[(2-methoxybenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-61-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(4-chlorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-62-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(3,4-dichlorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-63-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[(3-methoxybenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-64-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(1-naphthalenylcarbonyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-65-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(3-methylbenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-66-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(4-methylbenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-67-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(4-nitrobenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-68-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(3-nitrobenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-69-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(2-nitrobenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-70-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(3-chlorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-71-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(2-chlorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-72-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(2-fluorobenzoyl)amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-73-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[(2-methylbenzoyl)amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-74-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[[[(4-methylphenyl)amino]carbonyl]amino]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-75-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[[[(4-fluorophenyl)amino]carbonyl]amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-84-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-4-methyl-1-pentyl-1H-imidazol-5-yl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-85-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(2-iodo-5-methyl-1-pentyl-1H-imidazol-4-yl)ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-87-8 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-(2,4-dimethylphenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 652981-96-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-1-pentyl-1H-imidazol-4-yl]ethoxy]- (CA INDEX NAME)



RN 652981-97-0 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-4-methyl-1-pentyl-1H-imidazol-5-yl]ethoxy]- (CA INDEX NAME)



RN 652981-98-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-phenyl-1-(phenylmethyl)-1H-imidazol-4-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-99-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-phenyl-1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-00-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(methylthio)phenyl]-1-(phenylmethyl)-1H-imidazol-4-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-01-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-nitrophenyl)-1-(phenylmethyl)-1H-imidazol-4-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-02-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-1H-imidazol-4-yl]ethoxy]-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-03-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-1-pentyl-1H-imidazol-4-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-04-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-05-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-06-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-07-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-09-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-10-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(1,5-dimethyl-2-phenyl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-11-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-12-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-13-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-1,5-dimethyl-1H-imidazol-4-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-17-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[(1-pentyl-2-phenyl-1H-imidazol-5-yl)methoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-18-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[2-(4-methoxyphenyl)-1-pentyl-1H-imidazol-5-yl]methoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-19-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[1-pentyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]methoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-20-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[2-(1,3-benzodioxol-5-yl)-1-pentyl-1H-imidazol-5-yl]methoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-21-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[[2-(3,4-dimethylphenyl)-1-pentyl-1H-imidazol-5-yl]methoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-22-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[[1-pentyl-2-(4-pyridinyl)-1H-imidazol-5-yl]methoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-31-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(4-methylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-33-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-[(phenylmethyl)amino]phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-35-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-aminophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-36-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethenylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-37-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethenylphenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-38-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-(2-propenyl)phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-40-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-(4-propylphenyl)-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-47-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-bromophenyl)-1,4-dimethyl-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-48-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[1,4-dimethyl-2-[4-(1H-pyrrol-2-yl)phenyl]-1H-imidazol-5-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-74-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-80-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(5-ethoxy-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-81-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[3-(4-carboxyphenyl)-5-ethoxy-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-82-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(4-fluoro-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-83-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(4-chloro-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-84-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-85-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methoxy-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-86-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-87-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-fluoro-5-methoxy-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-88-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-fluoro-5-methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652982-89-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-bromo-5-methoxy-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 652982-90-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-3-phenyl-1H-pyrazol-1-yl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-96-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-[4-(1,1-dimethylethyl)phenyl]-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652982-97-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-(4-methoxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652982-99-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]-

1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-01-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-(1,3-benzodioxol-5-yl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-02-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-03-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-(4-ethylphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652983-04-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethoxy]-2,3-

dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-05-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[4-(4-carboxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-06-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[3,5-dimethyl-4-(4-methylphenyl)-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652983-07-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazol-1-yl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652983-08-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[3,5-dimethyl-4-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


1H-pyrazol-1-yl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 652983-13-6 CAPLUS


CN 3-Benzofuranacetic acid, 2,3-dihydro-6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 654650-48-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[(1,1-dimethylethoxy)carbonyl]amino]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 652980-44-4, (S)-[5-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid 652980-69-3, Ethyl (S)-[5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivs. as antidiabetic agents)

RN 652980-44-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 652980-69-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 652981-41-4P, Ethyl (S)-[5-[2-[5-methyl-2-(6-phenyl-3-pyridinyl)-1,3-oxazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate
 652981-46-9P, Ethyl (S)-[5-[2-(2-amino-5-methyl-1,3-thiazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652981-83-4P, Ethyl (S)-[5-[2-(2-iodo-5-methyl-1-trityl-1H-imidazol-4-yl)ethoxy]-2,3-dihydro-1H-inden-1-yl]acetate 652983-16-9P, Ethyl [6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-2,3-dihydrobenzofuran-3-yl]acetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indane, dihydrobenzofuran and tetrahydronaphthalene carboxylic acid derivs. as antidiabetic agents)

RN 652981-41-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(6-phenyl-3-pyridinyl)-4-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-46-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-amino-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 652981-83-4 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-iodo-5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 652983-16-9 CAPLUS

CN 3-Benzofuranacetic acid, 2,3-dihydro-6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:855915 CAPLUS Full-text

DOCUMENT NUMBER: 139:350727

TITLE: Preparation of indaneacetic acid derivatives for treating diabetes or diabetes-related disorders

INVENTOR(S): Wickens, Philip; Cantin, Louis-David; Kumarasinghe, Ellalahewage; Chuang, Chih-Yuan; Liang, Sidney X.

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 119 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089418	A1	20031030	WO 2003-US11725	20030416 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CN 1854118	A	20061101	CN 2006-10004609	20020725 <--
CA 2482714	A1	20031030	CA 2003-2482714	20030416 <--
AU 2003221960	A1	20031103	AU 2003-221960	20030416 <--
EP 1497271	A1	20050119	EP 2003-718423	20030416 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005526834	T	20050908	JP 2003-586139	20030416 <--
US 2005107392	A1	20050519	US 2004-506270	20040830 <--
US 2005075338	A1	20050407	US 2004-949119	20040922 <--


US 7112597	B2	20060926		
US 2006205723	A1	20060914	US 2006-429136	20060505 <--
PRIORITY APPLN. INFO.:			US 2002-373048P	P 20020416 <--
			US 2001-308500P	P 20010727 <--
			CN 2002-818676	A3 20020725 <--
			US 2002-205839	A1 20020725 <--
			WO 2003-US11725	W 20030416
			US 2004-949119	A3 20040922

OTHER SOURCE(S): MARPAT 139:350727

GI



I



II

AB The title compds. [I; R, R1 = H, alkyl; R2 = H, alkyl, (un)substituted Ph; R3 = H, halo, NO2, etc.; R4 = cycloalkyl, alkenyl, NO2, etc.; X = O, S], useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases, were prepared and formulated. E.g., a multi-step synthesis of (1S)-II, was given.

IT 496062-18-1P 496062-21-6P 496062-22-7P
 496062-23-8P 496062-24-9P 496062-25-0P
 496062-26-1P 496062-27-2P 496062-28-3P
 496062-29-4P 496062-30-7P 496062-31-8P
 496062-32-9P 496062-34-1P 496062-35-2P
 496062-36-3P 496062-37-4P 496062-38-5P
 496062-39-6P 496062-40-9P 496062-41-0P
 496062-42-1P 496062-44-3P 496062-45-4P
 496062-46-5P 496062-48-7P 496062-62-5P
 496062-63-6P 496062-64-7P 619299-00-2P
 619299-01-3P 619299-02-4P 619299-03-5P
 619299-04-6P 619299-05-7P 619299-06-8P
 619299-07-9P 619299-08-0P 619299-10-4P
 619299-12-6P 619299-13-7P 619299-14-8P
 619299-15-9P 619299-16-0P 619299-17-1P
 619299-18-2P 619299-19-3P 619299-20-6P
 619299-21-7P 619299-22-8P 619299-23-9P
 619299-24-0P 619299-25-1P 619299-26-2P
 619299-28-4P 619299-29-5P 619299-30-8P
 619299-31-9P 619299-32-0P 619299-33-1P
 619299-34-2P 619299-35-3P 619299-36-4P
 619299-37-5P 619299-38-6P 619299-39-7P
 619299-40-0P 619299-41-1P 619299-42-2P

619299-44-4P 619299-46-6P 619299-47-7P
 619299-50-2P 619299-51-3P 619299-54-6P
 619299-55-7P 619299-56-8P 619299-60-4P
 619299-65-9P 619299-67-1P 619299-68-2P
 619299-69-3P 619299-70-6P 619299-71-7P
 619299-72-8P 619299-73-9P 619299-78-4P
 619299-80-8P 619299-81-9P 619299-82-0P
 619299-83-1P 619299-84-2P 619299-85-3P
 619299-86-4P 619299-87-5P 619299-88-6P
 619299-89-7P 619299-90-0P 619299-91-1P
 619299-92-2P 619299-93-3P 619299-94-4P
 619299-95-5P 619299-96-6P 619299-97-7P
 619299-98-8P 619299-99-9P 619300-00-4P
 619300-01-5P 619300-02-6P 619300-03-7P
 619300-04-8P 619300-05-9P 619300-06-0P
 619300-08-2P 619300-09-3P 619300-10-6P
 619300-11-7P 619300-13-9P 619300-16-2P
 619300-17-3P 619300-18-4P 619300-19-5P
 619300-20-8P 619300-21-9P 619300-22-0P
 619300-23-1P 619300-24-2P 619300-25-3P
 619300-26-4P 619300-27-5P 619300-28-6P
 619300-29-7P 619300-30-0P 619300-31-1P
 619300-32-2P 619300-33-3P 619300-34-4P
 619300-35-5P 619300-36-6P 619300-37-7P
 619300-38-8P 619300-39-9P 619300-41-3P
 619300-42-4P 619300-44-6P 619300-45-7P
 619300-46-8P 619300-52-6P 619300-54-8P
 619300-55-9P 619300-56-0P 619300-57-1P
 619300-58-2P 619300-59-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indaneacetic acid derivs. for treating diabetes or diabetes-related disorders)

RN 496062-18-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry. .



RN 496062-21-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-22-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-23-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-24-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-25-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-26-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-cyanophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-27-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chloro-4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-28-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496062-29-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluorophenyl)-5-methyl-4-

thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-30-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-31-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-acetylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-32-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496062-34-1 CAPLUS
 CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 496062-33-0
 CMF C24 H26 N2 O3 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 496062-35-2 CAPLUS
 CN 1H-Indene-1-acetic acid, 5-[2-[2-(2-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 496062-36-3 CAPLUS
 CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-37-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-38-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-39-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-methylphenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-40-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-41-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-42-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,5-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-44-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-45-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(3-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-46-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-48-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(4-methyl-2-phenyl-5-oxazolyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-62-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-methylphenyl)-5-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-63-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluoro-4-methylphenyl)-4-methyl-5-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-64-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-00-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dimethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-01-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-(methylamino)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-02-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(acetamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-03-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(methanesulfonyl)amino]phenyl]-4-oxazolyl]ethoxy-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-04-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(acetamethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-05-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[methyl(methanesulfonyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 619299-06-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-07-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(ethylamino)-2-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-08-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(diethylamino)-2-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-10-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dimethylamino)-3-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-12-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-13-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-14-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(methylamino)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-15-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[methyl(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-16-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-aminophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-17-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[methyl(1-oxopropyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-18-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[[dimethylamino]carbonyl]methylamino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-19-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[(1-oxopropyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-20-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[[dimethylamino]carbonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-21-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[(ethylsulfonyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-22-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[[1-methylethyl)sulfonyl]amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-23-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[(dimethylamino)sulfonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-24-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[bis[(dimethylamino)sulfonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-25-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(ethylmethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-26-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619299-28-4 CAPLUS


CN Benzenaminium, 3-[4-[2-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-methyl-2-oxazolyl]-N,N,N-trimethyl-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 619299-27-3

CMF C26 H31 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 619299-29-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-30-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CO₂H

RN 619299-31-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




—CO₂H

RN 619299-32-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(diethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-33-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dipropylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-34-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[ethyl(phenylmethyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-35-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-[(phenylmethyl)propylamino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-36-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[butyl(phenylmethyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-37-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(ethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-38-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(propylamino)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-39-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(butylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-40-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[3-[(2-methoxyethyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-41-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[(2-ethoxyethyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-42-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-44-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-46-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-[methyl(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-47-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[ethyl(phenylmethyl)amino]-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-50-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-[(phenylmethyl)propylamino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-51-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-[butyl(phenylmethyl)amino]-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-54-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(ethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-55-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-(propylamino)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-56-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(butylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-60-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(diethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-65-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619299-67-1 CAPLUS


CN Benzenaminium, 5-[4-[2-[[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-methyl-2-oxazolyl]-2-methoxy-N,N,N-trimethyl-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 619299-66-0

CMF C27 H33 N2 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 619299-68-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(diethylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-69-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(ethylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-70-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dipropylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-71-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[4-methoxy-3-(propylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-72-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dibutylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-73-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(butylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-78-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dimethylamino)-4-methoxyphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-80-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(4-thiomorpholinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-81-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-piperidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-82-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-83-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dipropylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-84-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-pyrrolidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-85-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[4-(phenylmethyl)-1-piperazinyl]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

—CO₂H

RN 619299-86-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-[(2-ethoxyethyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-87-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-
[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-88-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-aminophenyl)-5-methyl-4-
oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-89-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(diethylamino)phenyl]-5-methyl-4-
oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-90-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-[(3S)-3-(dimethylamino)-1-
pyrrolidinyl]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA
INDEX NAME)


Absolute stereochemistry.



RN 619299-91-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-[(ethylsulfonyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-92-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-[[3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-93-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[[1-methyl-1H-imidazol-4-yl)sulfonyl]amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO₂H

RN 619299-94-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-
[(methylsulfonyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-95-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-
[(propylsulfonyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-96-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(acetamino)phenyl]-5-methyl-4-

oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-97-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[(1-oxopropyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-98-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[(2-methyl-1-oxopropyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619299-99-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-[[dimethylamino]carbonyl]amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-00-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[(2-thienylcarbonyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-01-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-[[2-(methylthio)-3-pyridinyl]carbonyl]amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-02-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-methyl-4-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-03-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[2-methyl-4-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-04-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-amino-3-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-05-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-amino-2-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-06-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(diethylamino)-3-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619300-08-2 CAPLUS

CN Benzenaminium, 4-[4-[2-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-


yl]oxy]ethyl]-5-methyl-2-oxazolyl]-N,N,N,3-tetramethyl-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 619300-07-1

CMF C27 H33 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 619300-09-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dipropylamino)-2-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-10-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[2-methyl-4-(propylamino)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-11-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dimethylamino)-2-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-13-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-16-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-ethenylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619300-17-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-ethylphenyl)-5-methyl-4-

oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-18-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(5-pyrimidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-19-5 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[4-[4-[2-[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-methyl-2-oxazolyl]phenyl]-, 1-(1,1-dimethylethyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-20-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-21-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(3-pyridinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-22-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(4-pyridinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-23-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-carboxy[1,1'-biphenyl]-4-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-24-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3'-nitro[1,1'-biphenyl])-4-yl]-4-oxazolyl]ethoxy-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-25-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1H-pyrrol-2-yl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-26-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3'-acetyl[1,1'-biphenyl])-4-yl]-5-methyl-4-oxazolyl]ethoxy-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-27-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(1,3-benzodioxol-5-yl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-28-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(4-pyridinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-29-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(3-pyridinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-30-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(2,4-dimethoxy-5-pyrimidinyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-31-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(3,5-dimethyl-4-isoxazolyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-32-2 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


—CO₂H

RN 619300-33-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-amino[1,1'-biphenyl]-3-yl)-5-methyl-4-

oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-34-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(1,3-benzodioxol-5-yl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-35-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(5-acetyl-2-thienyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-36-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[3-(4-methoxy-3-pyridinyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-37-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-cyclopentylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-38-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(5-pyrimidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-39-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-41-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromo-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-42-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromo-4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-44-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-(1H-pyrrol-2-yl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-45-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-amino-6-methyl[1,1'-biphenyl]-3-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619300-46-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-(5-

pyrimidinyl)phenyl]-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-52-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(3-methoxy-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-54-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxy-3-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-55-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[4-methoxy-3-(1H-pyrrol-2-yl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-56-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4'-amino-6-methoxy[1,1'-biphenyl]-3-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-57-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3'-amino-6-methoxy[1,1'-biphenyl]-3-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-58-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3'-amino-6-methyl[1,1'-biphenyl]-3-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-59-3 CAPLUS


CN 1H-Pyrrole-1-carboxylic acid, 2-[5-[4-[2-[[[(1S)-1-(carboxymethyl)-2,3-dihydro-1H-inden-5-yl]oxy]ethyl]-5-methyl-2-oxazolyl]-2-methoxyphenyl]-, 1-(1,1-dimethylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




IT 496063-18-4 619300-62-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of indaneacetic acid derivs. for treating diabetes or
 diabetes-related disorders)
 RN 496063-18-4 CAPLUS
 CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-bromophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 619300-62-8 CAPLUS
 CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-aminophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



IT 496062-17-0P 496062-47-6P 496062-59-0P
 496062-60-3P 496062-61-4P 496063-11-7P
 619298-92-9P 619298-93-0P 619298-94-1P
 619298-95-2P 619298-96-3P 619298-97-4P
 619298-98-5P 619298-99-6P 619299-11-5P
 619300-12-8P 619300-14-0P 619300-15-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of indaneacetic acid derivs. for treating diabetes or
 diabetes-related disorders)
 RN 496062-17-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-bromo-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-47-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(4-methyl-2-phenyl-5-oxazolyl)ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-59-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-60-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-methylphenyl)-5-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496062-61-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluoro-4-methylphenyl)-4-methyl-5-

oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496063-11-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-thiazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-92-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-bromo-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-93-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-[(phenylmethyl)amino]phenyl]-4-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-94-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-95-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(dimethylamino)-4-methylphenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-96-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-methyl-3-(methylamino)phenyl]-4-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-97-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(acetamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-98-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-bis(methylsulfonyl)amino]phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619298-99-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[3-(acetylmethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619299-11-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(4-

morpholinyl)phenyl]-4-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 619300-12-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OEt

RN 619300-14-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-ethenylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 619300-15-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:117811 CAPLUS Full-text

DOCUMENT NUMBER: 138:153524

TITLE: Preparation of indaneacetic acid derivatives for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases

INVENTOR(S): Lowe, Derek B.; Wickens, Philip L.; Ma, Xin; Zhang, Mingbao; Bullock, William H.; Coish, Philip D. G.; Mugge, Ingo A.; Stolle, Andreas; Wang, Ming; Wang, Yamin; Zhang, Chengzhi; Zhang, Hai-Jun; Zhu, Lei; Tsutsumi, Manami; Livingston, James N.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 189 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011842	A1	20030213	WO 2002-US23614	20020725 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

CA 2455620	A1	20030213	CA 2002-2455620	20020725 <--
AU 2002319693	A1	20030217	AU 2002-319693	20020725 <--
US 2003216391	A1	20031120	US 2002-205839	20020725 <--
US 6828335	B2	20041207		
EP 1414809	A1	20040506	EP 2002-750297	20020725 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1558905	A	20041229	CN 2002-818676	20020725 <--
JP 2005508308	T	20050331	JP 2003-517034	20020725 <--
BR 2002011502	A	20050920	BR 2002-11502	20020725 <--
NZ 531351	A	20060929	NZ 2002-531351	20020725 <--
CN 1854118	A	20061101	CN 2006-10004609	20020725 <--
HU 2007000105	A2	20070928	HU 2007-105	20020725 <--
RU 2314298	C2	20080110	RU 2004-105925	20020725 <--
MX 2004PA00599	A	20050217	MX 2004-PA599	20040120 <--
NO 2004000356	A	20040319	NO 2004-356	20040126 <--
IN 2004DN00258	A	20050401	IN 2004-DN258	20040205 <--
ZA 2004001517	A	20050310	ZA 2004-1517	20040225 <--
US 2005075338	A1	20050407	US 2004-949119	20040922 <--
US 7112597	B2	20060926		
US 2006205723	A1	20060914	US 2006-429136	20060505 <--
PRIORITY APPLN. INFO.:			US 2001-308500P	P 20010727 <--
			US 2002-373048P	P 20020416 <--
			CN 2002-818676	A3 20020725 <--
			US 2002-205839	A1 20020725 <--
			WO 2002-US23614	W 20020725 <--
			US 2004-949119	A3 20040922
OTHER SOURCE(S):			MARPAT 138:153524	
GI				



AB The title compds. I [R = H, alkyl; R1 = H, CO2R, cycloalkyl, etc.; R2 = H, halo, alkyl, etc.; R3 = H, alkyl, (un)substituted Ph; X = O, S; R4 = alkyl, cycloalkyl, Ph, etc.; R5 = H, halo, alkyl optionally substituted with oxo], useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases, were prepared and formulated. Thus, reacting 2-(4-methyl-2-phenyl-1,3-oxazol-5-yl)ethanol with Me 5-hydroxy-2,3-dihydroindene-1-yl-2-butanoate (prepn. given) in the presence of DEAD and PPh3 in THF followed by hydrolysis of the ester afforded the acid II.

IT 496061-81-5P 496062-47-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of indane acetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 496061-81-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-47-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(4-methyl-2-phenyl-5-oxazolyl)ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 496061-12-2P 496061-82-6P 496061-83-7P
 496061-84-8P 496061-85-9P 496061-86-0P
 496061-87-1P 496061-88-2P 496061-89-3P
 496061-90-6P 496061-91-7P 496061-92-8P
 496061-93-9P 496061-94-0P 496061-95-1P
 496061-96-2P 496061-97-3P 496061-98-4P
 496061-99-5P 496062-00-1P 496062-01-2P
 496062-02-3P 496062-03-4P 496062-04-5P
 496062-05-6P 496062-06-7P 496062-07-8P
 496062-08-9P 496062-09-0P 496062-10-3P
 496062-11-4P 496062-12-5P 496062-13-6P
 496062-14-7P 496062-18-1P 496062-21-6P
 496062-22-7P 496062-23-8P 496062-24-9P
 496062-25-0P 496062-26-1P 496062-27-2P
 496062-28-3P 496062-29-4P 496062-30-7P
 496062-31-8P 496062-32-9P 496062-34-1P
 496062-35-2P 496062-36-3P 496062-37-4P
 496062-38-5P 496062-39-6P 496062-40-9P
 496062-41-0P 496062-42-1P 496062-44-3P
 496062-45-4P 496062-46-5P 496062-48-7P
 496062-59-0P 496062-60-3P 496062-61-4P
 496062-62-5P 496062-63-6P 496062-64-7P
 496062-89-6P 496062-90-9P 496062-91-0P
 496062-92-1P 496063-11-7P 496063-23-1P
 496063-25-3P 496063-26-4P 496063-27-5P
 496063-28-6P 496063-29-7P 496063-30-0P


496063-31-1P 496063-32-2P 496063-34-4P
 496063-35-5P 496063-37-7P 496063-38-8P
 496063-39-9P 496063-40-2P 496063-41-3P
 496063-42-4P 496063-43-5P 496063-44-6P
 496063-45-7P 496063-46-8P 496063-47-9P
 496063-48-0P 496063-49-1P 496063-53-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indane acetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 496061-12-2 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)



RN 496061-82-6 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496061-83-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-84-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-85-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-86-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-87-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-88-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-89-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-butylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-90-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-91-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-92-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-93-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-94-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-benzo[b]thien-2-yl-5-methyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496061-95-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-96-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-cyclopentyl-5-methyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496061-97-3 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-(2-cyclohexyl-5-methyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496061-98-4 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(phenylmethyl)-4-

oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496061-99-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-00-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluoro-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-01-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-02-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(5-ethyl-2-phenyl-4-oxazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-03-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-04-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(2-phenyl-5-propyl-4-oxazolyl)ethoxy]- (CA INDEX NAME)




RN 496062-05-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-06-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-07-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496062-08-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-09-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-10-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-11-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496062-12-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[5-ethyl-2-(4-ethylphenyl)-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496062-13-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496062-14-7 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[5-ethyl-2-(4-methoxyphenyl)-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496062-18-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-21-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-22-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(4-methylphenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-23-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-24-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-25-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-26-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-cyanophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-27-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chloro-4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-28-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-29-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-30-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-31-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-acetylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-32-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 496062-34-1 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 496062-33-0

CMF C24 H26 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 496062-35-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-36-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-37-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-38-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-39-6 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-methylphenyl)-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-40-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-41-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-42-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,5-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-44-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-45-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(3-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-46-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-48-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(4-methyl-2-phenyl-5-oxazolyl)ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-59-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-60-3 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-methylphenyl)-5-oxazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-61-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluoro-4-methylphenyl)-4-methyl-5-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-62-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-(4-methylphenyl)-5-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-63-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluoro-4-methylphenyl)-4-methyl-5-oxazolyl]ethoxy]-2,3-dihydro-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-64-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-oxazolyl]ethoxy]-, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-89-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(5-acetyl-2-thienyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 496062-90-9 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[3-(1H-indol-5-yl)phenyl]-5-

methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)




RN 496062-91-0 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)



RN 496062-92-1 CAPLUS


CN 1H-Indene-1-acetic acid, 5-[2-[2-[4-(5-acetyl-2-thienyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496063-11-7 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-thiazolyl]ethoxy]-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 496063-23-1 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]- (CA INDEX NAME)




RN 496063-25-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(1,3-benzodioxol-5-yl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-26-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(4-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-27-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-28-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-cyanophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-29-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(1-methylethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-30-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-chloro-4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-31-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-32-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-34-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496063-35-5 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-acetylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-37-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-amino-4-methylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 496063-36-6


CMF C24 H26 N2 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 496063-38-8 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(2-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-39-9 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-40-2 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-ethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-41-3 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-42-4 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-(3-methylphenyl)-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-43-5 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-44-6 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3-fluorophenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-45-7 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(3,5-dimethylphenyl)-5-methyl-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-46-8 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-47-9 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-(3-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]- (CA INDEX NAME)




RN 496063-48-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro- (CA INDEX NAME)




RN 496063-49-1 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[5-ethyl-2-(4-ethylphenyl)-4-thiazolyl]ethoxy]-2,3-dihydro- (CA INDEX NAME)



RN 496063-53-7 CAPLUS

CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-[2-[4-(hydroxymethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]- (CA INDEX NAME)




IT 496063-16-2 496063-18-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indane acetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 496063-16-2 CAPLUS


CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, ethyl ester (CA INDEX NAME)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911255	A1	19990311	WO 1998-JP3760	19980825 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9887502	A	19990322	AU 1998-87502	19980825 <--
PRIORITY APPLN. INFO.:			JP 1997-233158	A 19970828 <--
			JP 1997-348825	A 19971218 <--
			WO 1998-JP3760	W 19980825 <--
OTHER SOURCE(S):			MARPAT 130:237567	
GI				



9168


AB Claimed are peroxisome proliferator-activated receptor controllers containing as the active ingredient compds. represented by general formula [I; R1 = C1-8 alkyl or alkoxy, halo, NO₂, CF₃; R2 = CO₂H, C1-4 alkoxy carbonyl, 1H-tetrazol-5-yl; A = single bond, :CH, C1-8 alkylene or C2-8 alkenylene, :CH-C1-8 alkylene, or :CH-C2-8 alkenylene (wherein one of C1-8 alkylene or C2-8 alkenylene carbon atoms is optionally replaced with S, SO, SO₂, O, NH, or alkyl-N); G = (un)substituted carbocyclic or heterocyclic; E1 = single bond, C1-8 alkylene, C2-8 alkenylene, C2-8 alkynylene; E2 = O, S, NH, C1-8 alkyl-N; E3 = single bond, C1-8 alkylene; n = 0,1; ring Cyc1 = absent, saturated, partially saturated, or unsatd. 5- to 7-membered carbocyclic ring; some provisos are given], nontoxic salts thereof, acid addition salts thereof or hydrates of the same. Because of the activity of controlling a peroxisome proliferator-activated receptor, the compds. of general formula I are useful as hypoglycemic agents, lipid-lowering agents, HDL cholesterol-increasing agents, LDL cholesterol- and/or VLDL cholesterol-lowering agents, risk factor decreasing agents for diabetes and syndrome X, and preventives and/or remedies for diseases caused by metabolic errors, such as diabetes, obesity, syndrome X, hypercholesterolemia and hyperlipoproteinemia, hyperlipemia, arteriosclerosis, hypertension, circulatory diseases, hyperphagia, and ischemic heart diseases. Thus, 5.98 g Me 6-(3-hydroxyphenyl)hexanoate (preparation given) was stirred with K₂CO₃ in DMF at room temperature for 5 min and then with 2-chloromethylquinoline hydrochloride 7.49, NaI 4.44, and Cs₂CO₃ 8.77 g at room temperature for 3 h to give Me 6-[3-(quinolin-2-ylmethoxy)phenyl]hexanoate (II; X = CH₂, R = Me). Preparation of 329 compds. I by the solid phase method on Wang resin was also described. II (X = S, R = H) mixed in a feed was fed to mice at 159 mg/kg/day for 8 consecutive days.



RN 496063-18-4 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-[2-(4-bromophenyl)-5-methyl-4-oxazolyl]ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 496062-17-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indane acetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 496062-17-0 CAPLUS

CN 1H-Indene-1-acetic acid, 5-[2-(2-bromo-5-methyl-4-thiazolyl)ethoxy]-2,3-dihydro-, ethyl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:184126 CAPLUS Full-text

DOCUMENT NUMBER: 130:237567

TITLE: Preparation of phenylalkanoic acid derivatives as peroxisome proliferator-activated receptor controllers

INVENTOR(S): Tajima, Hisao; Nakayama, Yoshisuke; Fukushima, Daikichi

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 252 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


The blood sugar level was 431 ± 76.4 , 309.4 ± 99.5 , and 324.5 ± 26.6 mg/dL on day 0, 6, and 9, resp., vs. 440.7 ± 102.7 , 442.6 ± 108.3 , and 518.8 ± 48.6 mg/dL, resp., for the control. The blood triglyceride level was 429.2 ± 80.6 , 248.8 ± 64.7 , and 260.6 ± 71.2 mg/dL on day 0, 6, and 9, resp., vs. 436.1 ± 97.5 , 367.6 ± 64.1 , and 272.3 ± 48.2 mg/dL, resp., for the control. A tablet and an ampule formulation containing II (X = CH₂, R = H) were described.

IT 221266-86-0P 221267-91-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylalkanoic acid derivs. as peroxisome proliferator-activated receptor controllers for treatment of diseases)


RN 221266-86-0 CAPLUS

CN 1-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-6-(2-quinolinylmethoxy)-, methyl ester (CA INDEX NAME)



RN 221267-91-0 CAPLUS

CN 1-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-6-(2-quinolinylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
40.30	231.29

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.80	-4.80

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 17:53:38 ON 01 FEB 2008